NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

Core Insights - NovaBridge Biosciences has entered into an exclusive license agreement with Everest Medicines for the development, manufacture, and commercialization of VIS-101 in Greater China and certain other Asian countries [1][5] - The appointment of Ian Woo to the Board of Directors is expected to enhance NovaBridge's strategic capabilities in biopharma finance and operations [2][3] Company Overview - NovaBridge is a global biotechnology platform focused on accelerating access to innovative medicines, combining business development expertise with clinical development [8] - Visara, a subsidiary of NovaBridge, is a clinical-stage biopharmaceutical company dedicated to developing best-in-class ophthalmic therapeutics [7] Product Details - VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, designed to provide more effective and durable treatment for conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [6][11] - The product is currently completing a Phase 2 study in China and is expected to be Phase 3-ready in 2026 [5][6] Strategic Collaboration - The partnership with Everest Medicines is seen as a strategic move to leverage their clinical and commercial expertise to accelerate the development of VIS-101 in Asia [2][5] - Everest Medicines will assume all payment obligations under the assigned license agreement and reimburse Visara for any upfront payments already made [2][5]